...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs
【24h】

TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs

机译：TC83复制子载体疫苗可为豚鼠提供抗朱宁病毒的保护

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Junin virus (JUNV) is the etiological agent of the potentially lethal, reemerging human disease, Argentine hemorrhagic fever (AHF). The mechanism of the disease development is not well understood and no antiviral therapy is available. Candid 1, a live-attenuated vaccine, has been developed by the US Army and is being used in the endemic area to prevent AHF. This vaccine is only approved for use in Argentina. In this study we have used the alphavirus-based approach to engineer a replicon system based on a human (United States Food and Drug Administration Investigational New Drug status) vaccine TC83 that express heterologous viral antigens, such as glycoproteins (GPC) of Junin virus (JUNV). Preclinical studies testing the immunogenicity and efficacy of TC83/GPC were performed in guinea pigs. A single dose of the live-attenuated alphavirus based vaccine expressing only GPC was immunogenic and provided partial protection, while a double dose of the same vaccine provided a complete protection against JUNV. This is the first scientific report to our knowledge that the immune response against GPC alone is sufficient to prevent lethal disease against JUNV in an animal model
机译：Junin病毒（JUNV）是可能致命的，正在重新出现的人类疾病阿根廷出血热（AHF）的病原体。疾病发展的机制尚不清楚，也没有抗病毒治疗可用。美国陆军已经研发出一种减毒活疫苗Candid 1，并在流行地区用于预防AHF。该疫苗仅获准在阿根廷使用。在这项研究中，我们使用了基于alpha病毒的方法来设计基于人类TC83疫苗的复制系统，该疫苗表达了异源病毒抗原，例如Junin病毒的糖蛋白（GPC）（ JUNV）。在豚鼠中进行了临床试验，以测试TC83 / GPC的免疫原性和功效。仅表达GPC的单剂量基于减毒活病毒的单剂疫苗具有免疫原性并提供部分保护，而同一剂量的双倍疫苗则可提供针对JUNV的完全保护。这是我们所知的第一份科学报告，即仅针对GPC的免疫反应就足以预防动物模型中针对JUNV的致死性疾病

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号